L G Poole1,2, A Pant1,2, K S Baker1,3, A K Kopec1,2, H M Cline-Fedewa2, S E Iismaa4, M J Flick5, J P Luyendyk1,2,3. 1. Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA. 2. Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI, USA. 3. Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, USA. 4. Division of Molecular Cardiology and Biophysics, Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia. 5. Cancer and Blood Diseases Institute, Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Abstract
Essentials Fibrin clots are often implicated in the progression of liver fibrosis. Liver fibrosis was induced in transgenic mice with defects in clot formation or stabilization. Liver fibrosis and fibrin(ogen) deposition do not require fibrin polymerization or factor XIIIa. Fibrin(ogen) is an in vivo substrate of tissue transglutaminase in experimental liver fibrosis. SUMMARY: Background Intravascular fibrin clots and extravascular fibrin deposits are often implicated in the progression of liver fibrosis. However, evidence supporting a pathological role of fibrin in hepatic fibrosis is indirect and based largely on studies using anticoagulant drugs that inhibit activation of the coagulation protease thrombin, which has other downstream targets that promote fibrosis. Therefore, the goal of this study was to determine the precise role of fibrin deposits in experimental hepatic fibrosis. Methods Liver fibrosis was induced in mice expressing mutant fibrinogen insensitive to thrombin-mediated proteolysis (i.e. locked in the monomeric form), termed FibAEK mice, and factor XIII A2 subunit-deficient (FXIII-/- ) mice. Female wild-type mice, FXIII-/- mice and homozygous FibAEK mice were challenged with carbon tetrachloride (CCl4 ) twice weekly for 4 weeks or 6 weeks (1 mL kg-1 , intraperitoneal). Results Hepatic injury and fibrosis induced by CCl4 challenge were unaffected by FXIII deficiency or inhibition of thrombin-catalyzed fibrin polymer formation (in FibAEK mice). Surprisingly, hepatic deposition of crosslinked fibrin(ogen) was not reduced in CCl4 -challenged FXIII-/- mice or FibAEK mice as compared with wild-type mice. Rather, deposition of crosslinked hepatic fibrin(ogen) following CCl4 challenge was dramatically reduced in tissue transglutaminase-2 (TGM2)-deficient (TGM2-/- ) mice. However, the reduction in crosslinked fibrin(ogen) in TGM2-/- mice did not affect CCl4 -induced liver fibrosis. Conclusions These results indicate that neither traditional fibrin clots, formed by the thrombin-activated FXIII pathway nor atypical TGM2-crosslinked fibrin(ogen) contribute to experimental CCl4 -induced liver fibrosis. Collectively, the results indicate that liver fibrosis occurs independently of intrahepatic fibrin(ogen) deposition.
Essentials Fibrin clots are often implicated in the progression of liver fibrosis. Liver fibrosis was induced in transgenic mice with defects in clot formation or stabilization. Liver fibrosis and fibrin(ogen) deposition do not require fibrin polymerization or factor XIIIa. Fibrin(ogen) is an in vivo substrate of tissue transglutaminase in experimental liver fibrosis. SUMMARY: Background Intravascular fibrin clots and extravascular fibrin deposits are often implicated in the progression of liver fibrosis. However, evidence supporting a pathological role of fibrin in hepatic fibrosis is indirect and based largely on studies using anticoagulant drugs that inhibit activation of the coagulation protease thrombin, which has other downstream targets that promote fibrosis. Therefore, the goal of this study was to determine the precise role of fibrin deposits in experimental hepatic fibrosis. Methods Liver fibrosis was induced in mice expressing mutant fibrinogen insensitive to thrombin-mediated proteolysis (i.e. locked in the monomeric form), termed FibAEK mice, and factor XIII A2 subunit-deficient (FXIII-/- ) mice. Female wild-type mice, FXIII-/- mice and homozygous FibAEK mice were challenged with carbon tetrachloride (CCl4 ) twice weekly for 4 weeks or 6 weeks (1 mL kg-1 , intraperitoneal). Results Hepatic injury and fibrosis induced by CCl4 challenge were unaffected by FXIII deficiency or inhibition of thrombin-catalyzed fibrin polymer formation (in FibAEK mice). Surprisingly, hepatic deposition of crosslinked fibrin(ogen) was not reduced in CCl4 -challenged FXIII-/- mice or FibAEK mice as compared with wild-type mice. Rather, deposition of crosslinked hepatic fibrin(ogen) following CCl4 challenge was dramatically reduced in tissue transglutaminase-2 (TGM2)-deficient (TGM2-/- ) mice. However, the reduction in crosslinked fibrin(ogen) in TGM2-/- mice did not affect CCl4 -induced liver fibrosis. Conclusions These results indicate that neither traditional fibrin clots, formed by the thrombin-activated FXIII pathway nor atypical TGM2-crosslinked fibrin(ogen) contribute to experimental CCl4 -induced liver fibrosis. Collectively, the results indicate that liver fibrosis occurs independently of intrahepatic fibrin(ogen) deposition.
Authors: Nikita Joshi; Anna K Kopec; Jessica L Ray; Holly Cline-Fedewa; Dafna J Groeneveld; Ton Lisman; James P Luyendyk Journal: Toxicol Appl Pharmacol Date: 2017-05-17 Impact factor: 4.219
Authors: Johannes Schindelin; Ignacio Arganda-Carreras; Erwin Frise; Verena Kaynig; Mark Longair; Tobias Pietzsch; Stephan Preibisch; Curtis Rueden; Stephan Saalfeld; Benjamin Schmid; Jean-Yves Tinevez; Daniel James White; Volker Hartenstein; Kevin Eliceiri; Pavel Tomancak; Albert Cardona Journal: Nat Methods Date: 2012-06-28 Impact factor: 28.547
Authors: Anna K Kopec; Nikita Joshi; Holly Cline-Fedewa; Anna V Wojcicki; Jessica L Ray; Bradley P Sullivan; John E Froehlich; Brendan F Johnson; Matthew J Flick; James P Luyendyk Journal: J Hepatol Date: 2016-12-10 Impact factor: 25.083
Authors: Elisabeth P C Plompen; Sarwa Darwish Murad; Bettina E Hansen; Daan W Loth; Jeoffrey N L Schouten; Pavel Taimr; Albert Hofman; André G Uitterlinden; Bruno H Stricker; Harry L A Janssen; Frank W G Leebeek Journal: J Hepatol Date: 2015-07-27 Impact factor: 25.083
Authors: Siiri E Iismaa; Mark Aplin; Sara Holman; Ting W Yiu; Kristy Jackson; James G Burchfield; Christopher J Mitchell; Liam O'Reilly; Aimee Davenport; James Cantley; Carsten Schmitz-Peiffer; Trevor J Biden; Gregory J Cooney; Robert M Graham Journal: PLoS One Date: 2013-05-22 Impact factor: 3.240
Authors: Lauren G Poole; Anna-Katherine Fournier; Holly M Cline-Fedewa; Anna K Kopec; James P Luyendyk; Dafna J Groeneveld Journal: Toxicology Date: 2021-10-04 Impact factor: 4.571
Authors: Dafna Groeneveld; Holly Cline-Fedewa; Kevin S Baker; Kurt J Williams; Robert A Roth; Karen Mittermeier; Ton Lisman; Joseph S Palumbo; James P Luyendyk Journal: J Hepatol Date: 2019-10-10 Impact factor: 30.083
Authors: Lauren G Poole; Anna K Kopec; Dafna J Groeneveld; Asmita Pant; Kevin S Baker; Holly M Cline-Fedewa; Matthew J Flick; James P Luyendyk Journal: Blood Date: 2021-05-06 Impact factor: 22.113
Authors: Lauren G Poole; Asmita Pant; Holly M Cline-Fedewa; Kurt J Williams; Bryan L Copple; Joseph S Palumbo; James P Luyendyk Journal: Res Pract Thromb Haemost Date: 2020-06-25